| Research and Development | 208.29K |
| General and Administrative | 468.03K |
| Depreciation and Amortization | |
| Consulting and Professional Fees | 220.5K |
| Impairment of Goodwill and Intangibles | |
| Total Costs and Expenses | 911.82K |
| OPERATING LOSS | -911.82K |
| Interest Expense | -16.59K |
| Interest Income | 300 |
| Other Income | |
| Gain on deconsolidation of Entest BioMedical | |
| Loss on sale of Available for Sale Securities | |
| Loss on disposal of Equipment | |
| Other Expense | |
| Other Losses attributable to Entest BioMedical, Inc. | |
| Total Other Income & (Expense) | |
| NET INCOME (LOSS) | |
| (NET INCOME) LOSS attributable to noncontrolling interest | |
| NET INCOME (LOSS) | |
| Equity in NET INCOME (LOSS) of Entest BioMedical | |
| NET INCOME (LOSS) available to Common Shareholders | |
| BASIC AND DILUTED EARNINGS (LOSS) PER SHARE | -0 |
| WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING | 5.57B |